胸腺素α1 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-09-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
| Property | Value | Notes |
|---|---|---|
| Residue count | 28 amino acids | Acetyl group on the first residue |
| Approximate molecular mass | 3108 daltons | Calculated from the consensus sequence |
| Origin | Cleavage product of prothymosin alpha | Not encoded as a separate gene product |
| Primary research focus | Immune modulation | Studied in viral hepatitis and as a vaccine adjuvant |
| Common synonyms | Thymalfasin, Tα1, thymosin alpha 1 | Thymalfasin is the assigned nonproprietary name |
Laboratory supplies of the peptide usually arrive as a lyophilized powder in sealed vials. The powder is hygroscopic, so a vial should be allowed to reach room temperature before it is opened to prevent condensation on the contents. Weighing and transfer are best performed in a low-humidity environment with clean tools. Once dissolved, the solution should be mixed gently rather than vortexed, because foaming and shear can reduce recovery of the peptide.
Storage recommendations center on low temperature, dryness, and protection from repeated freezing and thawing. The intact powder is commonly held at 20 degrees below zero Celsius or colder, while a working solution is divided into single-use aliquots to limit freeze-thaw cycles. Buffered saline or phosphate-buffered saline at neutral pH is frequently used as a diluent. Light sensitivity is not well documented, yet amber vials or foil wrapping are common practice for long-term storage of peptide stocks.
20世纪70年代，研究者从胸腺提取物中纯化出多种小肽，Tα1是其中被较早表征的一种。最初的制备依赖组织匀浆和层析步骤，产量低且成分复杂。随着固相肽合成技术成熟，实验室和工业界能够生产与天然序列一致的合成版本。合成肽的纯度可达95%以上，并可通过反相高效液相色谱和质谱进行鉴定。这一转变使研究不再依赖动物胸腺来源。
市售的胸腺素α1通常以冻干粉形式提供，溶解后用于注射。其氨基酸组成包括多个酸性残基，因此在中性pH下带负电荷。该肽可溶于水和生理盐水，但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度，溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。
胸腺素α1（thymosin alpha 1，Tα1）是一种由28个氨基酸组成的酸性肽，N端被乙酰化，分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离，属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守，提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置，并非表示亚型编号。它既存在于胸腺，也存在于脾脏和淋巴结等免疫组织。
== Further reading == Economy, Elizabeth C. (2018). The Third Revolution: Xi Jinping and the New Chinese State. Oxford University Press. ISBN 978-0-19-086607-5. Goodman, David S. G. (2015). Handbook of the Politics of China. Edward Elga. ISBN 978-1-78254-437-1. Li, Cheng (2014a). "Xi Jinping's Inner Circle (Part 2: Friends from Xi's Formative Years)" (PDF). Hoover Institution. Archived (PDF) from the original on 26 September 2020. Retrieved 15 July 2020. Simon, Denis Fred; Cong, Cao (2009). China's Emerging Technological Edge: Assessing the Role of High-End Talent. Cambridge University Press. ISBN 978-0-521-88513-3. Yang, Rufeng (2014). 習近平如何改變中國 [How Xi Jinping is changing China]. China Interpretation Series (in Chinese). Bonfire Limited. p. 12. ISBN 978-986-5721-05-3. Retrieved 23 August 2024. Zhu, Pengpeng (2007). 谜一样的人生 [A Mysterious Life] (in Chinese). Tianma Publishing. ISBN 978-0-9787999-2-2. Retrieved 23 August 2024.
==== Optical tweezers ==== Optical tweezers have also been used to separate cells in droplets. Two droplets are mixed on an electrode array, one containing the cells, and the other with nutrients or drugs. The droplets are mixed and then optical tweezers are used to move the cells to one side of the larger droplet before it is split. For a more detailed explanation on the underlying principles, see Optical tweezers.
. Whenever the integer nature of the number of agents is evident (populations with fewer than tens of thousands of individuals), inherent fluctuations in the disease spreading process caused by discrete agents result in uncertainties. In this scenario, the evolution of the disease predicted by compartmental equations deviates significantly from the observed results. These uncertainties may even cause the epidemic to end earlier than predicted by the compartmental equations. As a special case, one obtains the usual logistic function by assuming
Cyclone Tam causes significant power outages in Northland and leads to the cancellation of flights and ferry services in Auckland. 17 April – Cyclone Tam causes over 6,000 properties in Northland, the Coromandel Peninsula, Bay of Plenty and Gisborne to lose power overnight. 18 April – Cyclone Tam causes flooding to roads and highways in the Coromandel Peninsula. Flooding and strong-winds are also reported in the Far North District, leading to road closures and flight disruptions. 19 April – Cyclone Tam causes flooding, thunderstorms and travel disruptions in Auckland. Local authorities issue an emergency alert. 20 April: Auckland authorities issue a second emergency alert in response to flooding and thunderstorms caused by Cyclone Tam. 70 protesters affiliated with the Happy Valley Coalition occupy a fast-tracked coal mine on the Denniston Plateau near Westport. 21 April – Cyclone Tam begins easing, despite heavy rain and thunderstorms across New Zealand. Power companies work on restoring power to Northland homes. The Auckland Council inspects 16 flood-damaged properties. 22 April – Power companies restore power to most houses in Northland, with 25 Far North homes remaining disconnected. 23 April – Police remove the last remaining protesters from a coal mine in the Denniston Plateau. Seven people were charged with trespassing while three were arrested. 24 April – A fire breaks out at a recycling plant in the Wairau Valley in Auckland's North Shore, causing significant damage including a chemical spill contaminating several beaches in the North Shore.
Sources: en.wikipedia.org
For example, the energetics of the covalent bond to the serine molecule in chymotrypsin should be compared to the well-understood covalent bond to the nucleophile in the uncatalyzed solution reaction. A true proposal of a covalent catalysis (where the barrier is lower than the corresponding barrier in solution) would require, for example, a partial covalent bond to the transition state by an enzyme group (e.g., a very strong hydrogen bond), and such effects do not contribute significantly to catalysis.
These isoenzymes include MM, MB, and BB, which all carry out the same function given different amino acid sequences. The functions of these isoenzymes are to convert creatine, using ATP, into phosphocreatine expelling ADP. Mini columns were filled with DEAE-Sephadex A-50 and further eluted with tris- buffer sodium chloride at various concentrations (each concentration was chosen advantageously to manipulate elution). Human tissue extract was inserted in columns for separation. All fractions were analyzed to see total CK activity and it was found that each source of CK isoenzymes had characteristic isoenzymes found within. Firstly, CK- MM was eluted, then CK-MB, followed by CK-BB. Therefore, the isoenzymes found in each sample could be used to identify the source, as they were tissue specific. Using the information from results, correlation could be made about the diagnosis of patients and the kind of CK isoenzymes found in most abundant activity. From the finding, about 35 out of 71 patients studied suffered from heart attack (myocardial infarction) also contained an abundant amount of the CK-MM and CK-MB isoenzymes. Findings further show that many other diagnosis including renal failure, cerebrovascular disease, and pulmonary disease were only found to have the CK-MM isoenzyme and no other isoenzyme. The results from this study indicate correlations between various diseases and the CK isoenzymes found which confirms previous test results using various techniques.
Preventive medications may be recommended for those experiencing frequent or severe migraines. In particular, preventative drugs are recommended for individuals that experience more than 4 migraines per month, as well as for those where acute treatment does not work well. Preventive medications include beta blockers, topiramate, and calcitonin gene related peptides (CGRP) inhibitors like erenumab and galcanezumab. According to the European Headache Federation and American Headache Society, CGRP targeting therapies—which include both gepants and monoclonal antibodies—are a first-line option for migraine prevention. Botox injections can also help prevent migraine attacks, and are sometimes used for chronic migraines when other medications fail. For predicable menstrual migraines, a further option for prevention exist: the use of triptans in the two days before the period starts until three days after, or on the day the migraine is anticipated. This approach can be combined with other preventative drugs.
Sources: en.wikipedia.org
It is usually classified as an immunomodulatory peptide rather than a classical hormone. It derives from the larger protein prothymosin alpha and acts mainly on immune cells. The thymosin label covers a group of distinct peptides, so the naming can be misleading.
The two share a family name but have different sequences, sizes, and functions. Thymosin beta-4 is a 43-residue peptide associated with actin binding and cell migration. Thymosin alpha-1 is a 28-residue peptide linked mainly to immune signaling.
Thymalfasin is the assigned international nonproprietary name for the synthetic 28-residue peptide. Thymosin alpha-1 is the descriptive research name for the same molecule. Which term appears depends on the context and the regulatory document.
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.